Cowen and Company’s AEON Biopharma AEON Stock Holding History

Cowen and Company’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-139	Closed	-$70.8K	–	643
2023 Q2	$70.8K	Buy	+139	New	+$97.6K	0.01%	256

Other funds holding AEON

ACM

Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cowen and Company's AEON Position: Q3 2023 in Review

Cowen and Company sold out of AEON Biopharma (AEON) in Q3 2023, closing a stake of 139 shares — an estimated $70.8K sold.

Cowen and Company first reported a position in AEON in Q2 2023 and held it in 1 quarter. The position peaked at $70.8K in Q2 2023. 15 funds tracked by Wall St. Rank hold AEON as of Q3 2023.

Cowen and Company reported no remaining AEON Biopharma position as of Q3 2023 after selling out during the quarter.
Cowen and Company sold 139 AEON Biopharma shares in Q3 2023, an estimated $70.8K.
Cowen and Company first reported a position in AEON Biopharma in Q2 2023 and held it in 1 quarter.
Cowen and Company's AEON Biopharma position peaked at $70.8K in Q2 2023.
15 funds tracked by Wall St. Rank held AEON Biopharma as of Q3 2023.

Based on Cowen and Company's 13F filing for Q3 2023, filed 9 Nov 2023.